Variant position: 309 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: 393 The length of the canonical sequence.
Location on the sequence:
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human LRKKGEPH--HELPPGSTKRAL PNNTS-SSPQPK----KK----PLDGEYFT
Rhesus macaque FRKKGEPC--HQLPPGSTKRAL PNNTS-SSPQPK----KK-
Mouse FRKKEVLC--PELPPGSAKRAL PTCTS-ASPPQK----KK-
Rat FRKKEEHC--PELPPGSAKRAL PTSTS-SSPQQK----KK-
Pig FLKKGQSC--PEPPPGSTKRAL PTSTS-SSPVQK----KK-
Bovine LRKKGQSC--PEPPPRSTKRAL PTNTS-SSPQPK----KK-
Rabbit FRKKGEPC--PELPPGSSKRAL PTTTTDSSPQTK----KK-
Sheep FRKKGQSC--PEPPPGSTKRAL PSSTS-SSPQQK----KK-
Cat FRKKGEPC--PEPPPGSTKRAL PPSTS-STPPQK----KK-
Chicken FRKRGGAG-------GVAKRAM SPPTE-APEPPK----KR-
Xenopus laevis YTKKRGLK-----PSGKRELAH PPSSE--PPLPK----KRL
Zebrafish FKKDQETKTMAKTTTGTKRSLV KESSS-ATLRPEGSKKAK-
Sequence annotation in neighborhood: The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
Type: the type of sequence feature. Positions: endpoints of the sequence feature. Description: contains additional information about the feature.
Type Positions Description
1 – 393 Cellular tumor antigen p53
1 – 320 Interaction with CCAR2
100 – 370 Interaction with HIPK1
300 – 393 Interaction with CARM1
305 – 321 Bipartite nuclear localization signal
305 – 305 N6-acetyllysine
315 – 315 Phosphoserine; by AURKA, CDK1 and CDK2
321 – 321 N6-acetyllysine
291 – 291 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
292 – 292 Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin)
319 – 319 K -> A. Loss of nuclear localization; when associated with A-320 and A-321.
320 – 320 K -> A. Loss of nuclear localization; when associated with A-319 and A-321.
321 – 321 K -> A. Loss of nuclear localization; when associated with A-319 and A-320.
Identification of a tumor-rejection antigen recognized by HLA-B46 restricted CTL.
Azuma K.; Shichijo S.; Itoh K.;
Cited for: NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1); VARIANTS HIS-273 AND SER-309;
Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.